{"gene":"CNTN3","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1994,"finding":"CNTN3 (BIG-1/PANG) was identified as a GPI-anchored member of the TAG-1/F3 immunoglobulin superfamily with six Ig-like domains and four fibronectin type III repeats, expressed in subsets of neurons (Purkinje cells, dentate gyrus granule cells, cortical neurons), and recombinant BIG-1 protein promotes neurite outgrowth when used as a substrate for neurons in vitro.","method":"cDNA cloning, domain analysis, in vitro neurite outgrowth assay with recombinant protein","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1 — in vitro functional reconstitution of neurite outgrowth activity with recombinant protein, combined with molecular characterization","pmids":["8060619"],"is_preprint":false},{"year":1994,"finding":"CNTN3 (PANG) was identified as a ~113 kDa neuronal glycoprotein with six Ig C2-like and four fibronectin type III domains, normally expressed in brain, and ectopically activated by intracisternal A-type particle LTRs in murine plasmacytomas.","method":"cDNA cloning from plasmacytoma library, domain analysis, Northern blot, RT-PCR","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — molecular characterization and expression analysis but no direct functional assay in this paper","pmids":["8108413"],"is_preprint":false},{"year":1995,"finding":"CNTN3 (BIG-2) is a GPI-anchored AxCAM with six Ig-like domains and four fibronectin type III-like repeats; recombinant BIG-2 promotes neurite outgrowth in vitro, and in situ hybridization showed cell type-specific expression (high in CA1 pyramidal cells) distinct from related family members BIG-1, TAG-1, and F3.","method":"cDNA cloning, in vitro neurite outgrowth assay with recombinant protein, in situ hybridization","journal":"Journal of neurobiology","confidence":"High","confidence_rationale":"Tier 1 — in vitro neurite outgrowth reconstitution with recombinant protein, confirmed by molecular cloning and expression mapping","pmids":["8586965"],"is_preprint":false},{"year":1996,"finding":"The mouse Pang (Cntn3) gene was mapped to chromosome 6 between Wnt7a and Pcp1, and human PANG (CNTN3) was localized to chromosome 3p26 by somatic cell hybrid analysis.","method":"Somatic cell hybrid analysis, Southern blot","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromosomal mapping by somatic cell hybrids","pmids":["8661054"],"is_preprint":false},{"year":2019,"finding":"The second fibronectin type III domain (Fn(2)) of CNTN3 mediates binding to the Amyloid Precursor Protein (APP), and the copper-binding domain (CuBD) of APP mediates binding to CNTN3; alanine-scanning mutagenesis identified key residues on one face of CNTN3-Fn(2) and one face of APP-CuBD as the primary contact interface.","method":"Binding assays with APP-alkaline phosphatase fusion proteins and CNTN3-Fc fusion proteins, alanine substitution mutagenesis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding reconstitution combined with systematic mutagenesis to define the contact interface","pmids":["31318883"],"is_preprint":false},{"year":2026,"finding":"CNTN3 expression is transcriptionally regulated by PRRX2, which binds to the CNTN3 promoter; CNTN3 promotes colorectal cancer cell proliferation, inhibits apoptosis, and enhances epithelial-to-mesenchymal transition (EMT), migration, and invasion in vitro and tumor growth in vivo; PRRX2 knockdown reduces CNTN3 expression and reverses these phenotypes.","method":"Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, knockdown/rescue experiments, cell proliferation/apoptosis/migration/invasion assays, EMT marker detection, xenograft tumor model","journal":"Cell division","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, luciferase, functional assays, in vivo xenograft) from a single lab","pmids":["41882765"],"is_preprint":false}],"current_model":"CNTN3 is a GPI-anchored cell adhesion molecule of the immunoglobulin superfamily (six Ig-like domains, four fibronectin type III repeats) that promotes neurite outgrowth in vitro, with its second fibronectin domain (Fn2) directly binding the copper-binding domain of APP; it is expressed in a cell type-specific manner in the brain and, in non-neuronal contexts, its transcription is driven by PRRX2 to promote EMT and tumor cell invasion."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing that CNTN3 is a neurite outgrowth-promoting GPI-anchored Ig superfamily member answered the basic question of what molecular class this gene encodes and what neural function it supports.","evidence":"cDNA cloning with domain analysis and in vitro neurite outgrowth assay using recombinant BIG-1 protein as substrate for cultured neurons","pmids":["8060619","8108413"],"confidence":"High","gaps":["In vivo loss-of-function or gain-of-function studies not performed","Receptor or co-receptor mediating neurite outgrowth signal not identified","Mechanism by which GPI-anchored CNTN3 transduces a signal across the membrane unknown"]},{"year":1995,"claim":"Demonstrating that the related BIG-2 isoform also promotes neurite outgrowth and mapping its distinct expression pattern (e.g., CA1 pyramidal cells) established that contactin family members have overlapping biochemical activities but spatially segregated expression domains in the brain.","evidence":"Recombinant BIG-2 neurite outgrowth assay and in situ hybridization comparing BIG-1, BIG-2, TAG-1, and F3 expression","pmids":["8586965"],"confidence":"High","gaps":["Functional redundancy versus specificity among contactin family members not tested","Ligand or cis-interacting partner mediating neurite outgrowth not identified"]},{"year":2019,"claim":"Mapping the CNTN3-APP binding interface to the Fn2 domain of CNTN3 and the copper-binding domain of APP answered a long-standing question about the molecular partners of CNTN3 and provided a candidate trans-synaptic signaling axis.","evidence":"In vitro binding assays with alkaline phosphatase and Fc fusion proteins combined with systematic alanine-scanning mutagenesis","pmids":["31318883"],"confidence":"High","gaps":["Functional consequence of CNTN3-APP interaction on APP processing or neuronal signaling not determined","Whether the interaction occurs in trans (cell-cell) or in cis on the same membrane not resolved","In vivo relevance of the CNTN3-APP interaction not tested"]},{"year":2026,"claim":"Identifying PRRX2 as a direct transcriptional activator of CNTN3 and showing that CNTN3 promotes EMT, invasion, and tumor growth in colorectal cancer revealed a non-neuronal oncogenic role and an upstream regulatory mechanism.","evidence":"ChIP and dual-luciferase reporter assays for PRRX2-promoter binding; knockdown/rescue experiments, proliferation/apoptosis/migration/invasion assays, EMT marker detection, and xenograft tumor model in colorectal cancer cells","pmids":["41882765"],"confidence":"Medium","gaps":["Findings from a single laboratory; independent replication in additional cancer cohorts needed","Downstream signaling pathway through which CNTN3 promotes EMT not defined","Whether the GPI-anchored form or a shed soluble form mediates the oncogenic phenotype is unknown"]},{"year":null,"claim":"The in vivo neuronal function of CNTN3 — including phenotypes of knockout animals, the signaling consequence of CNTN3-APP interaction, and how CNTN3 transduces signals across the membrane as a GPI-anchored protein — remains uncharacterized.","evidence":"","pmids":[],"confidence":"Low","gaps":["No knockout or conditional knockout phenotype reported","No identified transmembrane co-receptor or signaling adaptor for CNTN3","Structural basis of the CNTN3-APP complex not solved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2]}],"pathway":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2]}],"complexes":[],"partners":["APP"],"other_free_text":[]},"mechanistic_narrative":"CNTN3 is a GPI-anchored immunoglobulin superfamily cell adhesion molecule containing six Ig-like domains and four fibronectin type III repeats that promotes neurite outgrowth in vitro and is expressed in a cell type-specific pattern in brain neurons including Purkinje cells, dentate gyrus granule cells, and CA1 pyramidal cells [PMID:8060619, PMID:8586965]. Its second fibronectin type III domain (Fn2) directly binds the copper-binding domain of amyloid precursor protein (APP), with key contact residues mapped by alanine-scanning mutagenesis [PMID:31318883]. In a non-neuronal context, CNTN3 transcription is driven by PRRX2 binding to its promoter, and CNTN3 promotes epithelial-to-mesenchymal transition, migration, invasion, and tumor growth in colorectal cancer cells [PMID:41882765]."},"prefetch_data":{"uniprot":{"accession":"Q9P232","full_name":"Contactin-3","aliases":["Brain-derived immunoglobulin superfamily protein 1","BIG-1","Plasmacytoma-associated neuronal glycoprotein"],"length_aa":1028,"mass_kda":112.9,"function":"Contactins mediate cell surface interactions during nervous system development. Has some neurite outgrowth-promoting activity (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9P232/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CNTN3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CNTN3","total_profiled":1310},"omim":[{"mim_id":"609739","title":"IMMUNOGLOBULIN-LIKE DOMAIN-CONTAINING RECEPTOR 1; ILDR1","url":"https://www.omim.org/entry/609739"},{"mim_id":"609646","title":"DEAFNESS, AUTOSOMAL RECESSIVE 42; DFNB42","url":"https://www.omim.org/entry/609646"},{"mim_id":"607220","title":"CONTACTIN 6; CNTN6","url":"https://www.omim.org/entry/607220"},{"mim_id":"607219","title":"CONTACTIN 5; CNTN5","url":"https://www.omim.org/entry/607219"},{"mim_id":"601325","title":"CONTACTIN 3; CNTN3","url":"https://www.omim.org/entry/601325"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CNTN3"},"hgnc":{"alias_symbol":["BIG-1"],"prev_symbol":["PANG"]},"alphafold":{"accession":"Q9P232","domains":[{"cath_id":"2.60.40.10","chopping":"25-120","consensus_level":"high","plddt":89.5465,"start":25,"end":120},{"cath_id":"2.60.40.10","chopping":"127-224","consensus_level":"medium","plddt":91.8302,"start":127,"end":224},{"cath_id":"2.60.40.10","chopping":"324-405","consensus_level":"medium","plddt":90.8165,"start":324,"end":405},{"cath_id":"2.60.40.10","chopping":"407-488","consensus_level":"high","plddt":87.4116,"start":407,"end":488},{"cath_id":"2.60.40.10","chopping":"502-596","consensus_level":"high","plddt":85.4866,"start":502,"end":596},{"cath_id":"2.60.40.10","chopping":"608-616_626-696","consensus_level":"high","plddt":93.2859,"start":608,"end":696},{"cath_id":"2.60.40.10","chopping":"706-798","consensus_level":"medium","plddt":89.6438,"start":706,"end":798},{"cath_id":"2.60.40.10","chopping":"808-898","consensus_level":"medium","plddt":86.8974,"start":808,"end":898},{"cath_id":"2.60.40.10","chopping":"909-992","consensus_level":"medium","plddt":82.8918,"start":909,"end":992}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P232","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P232-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P232-F1-predicted_aligned_error_v6.png","plddt_mean":86.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CNTN3","jax_strain_url":"https://www.jax.org/strain/search?query=CNTN3"},"sequence":{"accession":"Q9P232","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9P232.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9P232/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P232"}},"corpus_meta":[{"pmid":"17200148","id":"PMC_17200148","title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17200148","citation_count":710,"is_preprint":false},{"pmid":"22018631","id":"PMC_22018631","title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.","date":"2011","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22018631","citation_count":304,"is_preprint":false},{"pmid":"24912899","id":"PMC_24912899","title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).","date":"2014","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24912899","citation_count":195,"is_preprint":false},{"pmid":"8586965","id":"PMC_8586965","title":"Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: four members of an axon-associated cell adhesion molecule subgroup of the immunoglobulin superfamily.","date":"1995","source":"Journal of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8586965","citation_count":141,"is_preprint":false},{"pmid":"26215945","id":"PMC_26215945","title":"Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.","date":"2015","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26215945","citation_count":132,"is_preprint":false},{"pmid":"18083065","id":"PMC_18083065","title":"Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.","date":"2007","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18083065","citation_count":129,"is_preprint":false},{"pmid":"28380313","id":"PMC_28380313","title":"Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.","date":"2017","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28380313","citation_count":104,"is_preprint":false},{"pmid":"21570352","id":"PMC_21570352","title":"TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.","date":"2011","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21570352","citation_count":104,"is_preprint":false},{"pmid":"17301074","id":"PMC_17301074","title":"Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.","date":"2007","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17301074","citation_count":103,"is_preprint":false},{"pmid":"17998546","id":"PMC_17998546","title":"Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17998546","citation_count":102,"is_preprint":false},{"pmid":"8060619","id":"PMC_8060619","title":"BIG-1: a new TAG-1/F3-related member of the immunoglobulin superfamily with neurite outgrowth-promoting activity.","date":"1994","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/8060619","citation_count":93,"is_preprint":false},{"pmid":"30475668","id":"PMC_30475668","title":"Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.","date":"2018","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30475668","citation_count":85,"is_preprint":false},{"pmid":"31377477","id":"PMC_31377477","title":"Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.","date":"2019","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/31377477","citation_count":63,"is_preprint":false},{"pmid":"21635709","id":"PMC_21635709","title":"Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.","date":"2011","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/21635709","citation_count":58,"is_preprint":false},{"pmid":"30335191","id":"PMC_30335191","title":"Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.","date":"2018","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30335191","citation_count":58,"is_preprint":false},{"pmid":"29893791","id":"PMC_29893791","title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.","date":"2018","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29893791","citation_count":54,"is_preprint":false},{"pmid":"22084092","id":"PMC_22084092","title":"Effects of brefeldin A-inhibited guanine nucleotide-exchange (BIG) 1 and KANK1 proteins on cell polarity and directed migration during wound healing.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22084092","citation_count":34,"is_preprint":false},{"pmid":"19528136","id":"PMC_19528136","title":"Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.","date":"2009","source":"Clinical trials (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19528136","citation_count":33,"is_preprint":false},{"pmid":"28527420","id":"PMC_28527420","title":"Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.","date":"2017","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/28527420","citation_count":29,"is_preprint":false},{"pmid":"19020088","id":"PMC_19020088","title":"Interaction of brefeldin A-inhibited guanine nucleotide-exchange protein (BIG) 1 and kinesin motor protein KIF21A.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19020088","citation_count":28,"is_preprint":false},{"pmid":"23116626","id":"PMC_23116626","title":"Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.","date":"2012","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/23116626","citation_count":27,"is_preprint":false},{"pmid":"25935582","id":"PMC_25935582","title":"CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.","date":"2015","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/25935582","citation_count":27,"is_preprint":false},{"pmid":"8108413","id":"PMC_8108413","title":"PANG, a gene encoding a neuronal glycoprotein, is ectopically activated by intracisternal A-type particle long terminal repeats in murine plasmacytomas.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8108413","citation_count":26,"is_preprint":false},{"pmid":"23243306","id":"PMC_23243306","title":"PanG, a new ketopantoate reductase involved in pantothenate synthesis.","date":"2012","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/23243306","citation_count":19,"is_preprint":false},{"pmid":"32566650","id":"PMC_32566650","title":"SLC1A1, SLC16A9, and CNTN3 Are Potential Biomarkers for the Occurrence of Colorectal Cancer.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32566650","citation_count":18,"is_preprint":false},{"pmid":"18650162","id":"PMC_18650162","title":"A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.","date":"2008","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18650162","citation_count":18,"is_preprint":false},{"pmid":"26590813","id":"PMC_26590813","title":"ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.","date":"2015","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/26590813","citation_count":16,"is_preprint":false},{"pmid":"37692921","id":"PMC_37692921","title":"Characterization of Thermostable Cellulase from Bacillus licheniformis PANG L Isolated from the Himalayan Soil.","date":"2023","source":"International journal of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/37692921","citation_count":15,"is_preprint":false},{"pmid":"18784962","id":"PMC_18784962","title":"Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.","date":"2008","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18784962","citation_count":15,"is_preprint":false},{"pmid":"30899086","id":"PMC_30899086","title":"Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.","date":"2019","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30899086","citation_count":14,"is_preprint":false},{"pmid":"19914548","id":"PMC_19914548","title":"Update of the BIG 1-98 Trial: where do we stand?","date":"2009","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/19914548","citation_count":13,"is_preprint":false},{"pmid":"33159633","id":"PMC_33159633","title":"Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.","date":"2020","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33159633","citation_count":10,"is_preprint":false},{"pmid":"20144231","id":"PMC_20144231","title":"Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20144231","citation_count":9,"is_preprint":false},{"pmid":"32652112","id":"PMC_32652112","title":"Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.","date":"2020","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32652112","citation_count":7,"is_preprint":false},{"pmid":"16730270","id":"PMC_16730270","title":"The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.","date":"2006","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16730270","citation_count":6,"is_preprint":false},{"pmid":"26387144","id":"PMC_26387144","title":"Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.","date":"2015","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26387144","citation_count":6,"is_preprint":false},{"pmid":"27459313","id":"PMC_27459313","title":"Retraction statement: ‘Urotensin II inhibits autophagy in renal tubular epithelial cells and induces extracellular matrix production in early diabetic mice’ by Guan‐Jong Chen, Fei Wu, Xin‐Xin Pang, Ai‐Hua Zhang, Jun‐Bao Shi, Min Lu and Chao‐Shu Tang.","date":"2016","source":"Journal of diabetes investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27459313","citation_count":5,"is_preprint":false},{"pmid":"28027521","id":"PMC_28027521","title":"Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.","date":"2016","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/28027521","citation_count":5,"is_preprint":false},{"pmid":"34486302","id":"PMC_34486302","title":"Comparison of Grain Processing Techniques on Saponin Content and Nutritional Value of Quinoa (Chenopodium quinoa Cv. Yellow Pang-da) Grain.","date":"2021","source":"Pakistan journal of biological sciences : PJBS","url":"https://pubmed.ncbi.nlm.nih.gov/34486302","citation_count":5,"is_preprint":false},{"pmid":"31853266","id":"PMC_31853266","title":"An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).","date":"2019","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31853266","citation_count":5,"is_preprint":false},{"pmid":"19096768","id":"PMC_19096768","title":"Understanding the BIG results: Insights from the BIG 1-98 trial analyses.","date":"2008","source":"Advances in therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19096768","citation_count":4,"is_preprint":false},{"pmid":"40055382","id":"PMC_40055382","title":"Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.","date":"2025","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40055382","citation_count":4,"is_preprint":false},{"pmid":"8661054","id":"PMC_8661054","title":"Plasmacytoma-associated neuronal glycoprotein, Pang, maps to mouse chromosome 6 and human chromosome 3.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661054","citation_count":4,"is_preprint":false},{"pmid":"31318883","id":"PMC_31318883","title":"Defining the binding interface of Amyloid Precursor Protein (APP) and Contactin3 (CNTN3) by site-directed mutagenesis.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31318883","citation_count":3,"is_preprint":false},{"pmid":"31800174","id":"PMC_31800174","title":"PLLA/POSS Nanofibers Loaded with Multitargeted pANG Composite Nanoparticles for Promotion of Vascularization in Shear Flow.","date":"2019","source":"Macromolecular bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/31800174","citation_count":3,"is_preprint":false},{"pmid":"19785285","id":"PMC_19785285","title":"Identification and characterization of a psychrophilic yeast strain newly isolated from the fermentative starter (Loog-pang) of a traditional drink in Thailand.","date":"2009","source":"Biocontrol science","url":"https://pubmed.ncbi.nlm.nih.gov/19785285","citation_count":3,"is_preprint":false},{"pmid":"40824521","id":"PMC_40824521","title":"Probiotic potential and phytase-producing capacity of yeast isolated from Thai traditional fermentation starter (Look-pang).","date":"2025","source":"Folia microbiologica","url":"https://pubmed.ncbi.nlm.nih.gov/40824521","citation_count":1,"is_preprint":false},{"pmid":"32337480","id":"PMC_32337480","title":"Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.","date":"2019","source":"JNCI cancer spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/32337480","citation_count":1,"is_preprint":false},{"pmid":"41882765","id":"PMC_41882765","title":"PRRX2-CNTN3 axis promotes epithelial-to-mesenchymal transition and metastasis in colorectal cancer.","date":"2026","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/41882765","citation_count":0,"is_preprint":false},{"pmid":"41419752","id":"PMC_41419752","title":"Chromosome-level genome assembly of Trichogramma ostriniae Pang & Chen (Hymenoptera: Trichogrammatidae).","date":"2025","source":"Scientific data","url":"https://pubmed.ncbi.nlm.nih.gov/41419752","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32067,"output_tokens":1520,"usd":0.0595},"stage2":{"model":"claude-opus-4-6","input_tokens":4755,"output_tokens":1453,"usd":0.09015},"total_usd":0.14965,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"CNTN3 (BIG-1/PANG) was identified as a GPI-anchored member of the TAG-1/F3 immunoglobulin superfamily with six Ig-like domains and four fibronectin type III repeats, expressed in subsets of neurons (Purkinje cells, dentate gyrus granule cells, cortical neurons), and recombinant BIG-1 protein promotes neurite outgrowth when used as a substrate for neurons in vitro.\",\n      \"method\": \"cDNA cloning, domain analysis, in vitro neurite outgrowth assay with recombinant protein\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro functional reconstitution of neurite outgrowth activity with recombinant protein, combined with molecular characterization\",\n      \"pmids\": [\"8060619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CNTN3 (PANG) was identified as a ~113 kDa neuronal glycoprotein with six Ig C2-like and four fibronectin type III domains, normally expressed in brain, and ectopically activated by intracisternal A-type particle LTRs in murine plasmacytomas.\",\n      \"method\": \"cDNA cloning from plasmacytoma library, domain analysis, Northern blot, RT-PCR\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — molecular characterization and expression analysis but no direct functional assay in this paper\",\n      \"pmids\": [\"8108413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CNTN3 (BIG-2) is a GPI-anchored AxCAM with six Ig-like domains and four fibronectin type III-like repeats; recombinant BIG-2 promotes neurite outgrowth in vitro, and in situ hybridization showed cell type-specific expression (high in CA1 pyramidal cells) distinct from related family members BIG-1, TAG-1, and F3.\",\n      \"method\": \"cDNA cloning, in vitro neurite outgrowth assay with recombinant protein, in situ hybridization\",\n      \"journal\": \"Journal of neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro neurite outgrowth reconstitution with recombinant protein, confirmed by molecular cloning and expression mapping\",\n      \"pmids\": [\"8586965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The mouse Pang (Cntn3) gene was mapped to chromosome 6 between Wnt7a and Pcp1, and human PANG (CNTN3) was localized to chromosome 3p26 by somatic cell hybrid analysis.\",\n      \"method\": \"Somatic cell hybrid analysis, Southern blot\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping by somatic cell hybrids\",\n      \"pmids\": [\"8661054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The second fibronectin type III domain (Fn(2)) of CNTN3 mediates binding to the Amyloid Precursor Protein (APP), and the copper-binding domain (CuBD) of APP mediates binding to CNTN3; alanine-scanning mutagenesis identified key residues on one face of CNTN3-Fn(2) and one face of APP-CuBD as the primary contact interface.\",\n      \"method\": \"Binding assays with APP-alkaline phosphatase fusion proteins and CNTN3-Fc fusion proteins, alanine substitution mutagenesis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding reconstitution combined with systematic mutagenesis to define the contact interface\",\n      \"pmids\": [\"31318883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CNTN3 expression is transcriptionally regulated by PRRX2, which binds to the CNTN3 promoter; CNTN3 promotes colorectal cancer cell proliferation, inhibits apoptosis, and enhances epithelial-to-mesenchymal transition (EMT), migration, and invasion in vitro and tumor growth in vivo; PRRX2 knockdown reduces CNTN3 expression and reverses these phenotypes.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, knockdown/rescue experiments, cell proliferation/apoptosis/migration/invasion assays, EMT marker detection, xenograft tumor model\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, luciferase, functional assays, in vivo xenograft) from a single lab\",\n      \"pmids\": [\"41882765\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNTN3 is a GPI-anchored cell adhesion molecule of the immunoglobulin superfamily (six Ig-like domains, four fibronectin type III repeats) that promotes neurite outgrowth in vitro, with its second fibronectin domain (Fn2) directly binding the copper-binding domain of APP; it is expressed in a cell type-specific manner in the brain and, in non-neuronal contexts, its transcription is driven by PRRX2 to promote EMT and tumor cell invasion.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CNTN3 is a GPI-anchored immunoglobulin superfamily cell adhesion molecule containing six Ig-like domains and four fibronectin type III repeats that promotes neurite outgrowth in vitro and is expressed in a cell type-specific pattern in brain neurons including Purkinje cells, dentate gyrus granule cells, and CA1 pyramidal cells [PMID:8060619, PMID:8586965]. Its second fibronectin type III domain (Fn2) directly binds the copper-binding domain of amyloid precursor protein (APP), with key contact residues mapped by alanine-scanning mutagenesis [PMID:31318883]. In a non-neuronal context, CNTN3 transcription is driven by PRRX2 binding to its promoter, and CNTN3 promotes epithelial-to-mesenchymal transition, migration, invasion, and tumor growth in colorectal cancer cells [PMID:41882765].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that CNTN3 is a neurite outgrowth-promoting GPI-anchored Ig superfamily member answered the basic question of what molecular class this gene encodes and what neural function it supports.\",\n      \"evidence\": \"cDNA cloning with domain analysis and in vitro neurite outgrowth assay using recombinant BIG-1 protein as substrate for cultured neurons\",\n      \"pmids\": [\"8060619\", \"8108413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo loss-of-function or gain-of-function studies not performed\",\n        \"Receptor or co-receptor mediating neurite outgrowth signal not identified\",\n        \"Mechanism by which GPI-anchored CNTN3 transduces a signal across the membrane unknown\"\n      ]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that the related BIG-2 isoform also promotes neurite outgrowth and mapping its distinct expression pattern (e.g., CA1 pyramidal cells) established that contactin family members have overlapping biochemical activities but spatially segregated expression domains in the brain.\",\n      \"evidence\": \"Recombinant BIG-2 neurite outgrowth assay and in situ hybridization comparing BIG-1, BIG-2, TAG-1, and F3 expression\",\n      \"pmids\": [\"8586965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional redundancy versus specificity among contactin family members not tested\",\n        \"Ligand or cis-interacting partner mediating neurite outgrowth not identified\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapping the CNTN3-APP binding interface to the Fn2 domain of CNTN3 and the copper-binding domain of APP answered a long-standing question about the molecular partners of CNTN3 and provided a candidate trans-synaptic signaling axis.\",\n      \"evidence\": \"In vitro binding assays with alkaline phosphatase and Fc fusion proteins combined with systematic alanine-scanning mutagenesis\",\n      \"pmids\": [\"31318883\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequence of CNTN3-APP interaction on APP processing or neuronal signaling not determined\",\n        \"Whether the interaction occurs in trans (cell-cell) or in cis on the same membrane not resolved\",\n        \"In vivo relevance of the CNTN3-APP interaction not tested\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identifying PRRX2 as a direct transcriptional activator of CNTN3 and showing that CNTN3 promotes EMT, invasion, and tumor growth in colorectal cancer revealed a non-neuronal oncogenic role and an upstream regulatory mechanism.\",\n      \"evidence\": \"ChIP and dual-luciferase reporter assays for PRRX2-promoter binding; knockdown/rescue experiments, proliferation/apoptosis/migration/invasion assays, EMT marker detection, and xenograft tumor model in colorectal cancer cells\",\n      \"pmids\": [\"41882765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Findings from a single laboratory; independent replication in additional cancer cohorts needed\",\n        \"Downstream signaling pathway through which CNTN3 promotes EMT not defined\",\n        \"Whether the GPI-anchored form or a shed soluble form mediates the oncogenic phenotype is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The in vivo neuronal function of CNTN3 — including phenotypes of knockout animals, the signaling consequence of CNTN3-APP interaction, and how CNTN3 transduces signals across the membrane as a GPI-anchored protein — remains uncharacterized.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No knockout or conditional knockout phenotype reported\",\n        \"No identified transmembrane co-receptor or signaling adaptor for CNTN3\",\n        \"Structural basis of the CNTN3-APP complex not solved\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APP\"],\n    \"other_free_text\": []\n  }\n}\n```"}